REVB
Revelation Biosciences Inc
NASDAQ: REVB · HEALTHCARE · BIOTECHNOLOGY
$0.81
-5.27% today
Updated 2026-09-29
Market cap
$3.71M
P/E ratio
0.03
P/S ratio
2.88x
EPS (TTM)
$27.03
Dividend yield
—
52W range
$1 – $7
Volume
0.0M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D6.7
Valuation
B3/9
Piotroski F-Score
Weak
-5.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →262 stocks currently score above 75
Price targets
Analyst target
$17.75
+2080.59%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.07x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -5.69 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-2.60M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-10.83M | $-120254.00 | $-15.04M | $-8.91M | $-3.32M |
| EPS | — | — | — | — | $27.03 |
| Free cash flow | $-11.22M | $-7.29M | $-18.34M | $-8.27M | $-2.60M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Revelation Biosciences Inc trades at $0.81. representing a P/E of 0.03x trailing earnings. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -5.69, it sits in the distress.
Frequently asked questions
What is Revelation Biosciences Inc's stock price?
Revelation Biosciences Inc (REVB) trades at $0.81, on a P/E of 0.0x and a P/S of 2.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Revelation Biosciences Inc overvalued?
Revelation Biosciences Inc carries a Smart Value Score of 31/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Revelation Biosciences Inc (REVB)?
The 12-month analyst consensus target is $17.75, about 2080.6% above the current $0.81. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Revelation Biosciences Inc's Altman Z-Score is -5.69, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.88x
ROE-76.00%
Beta-0.14
50D MA$1.05
200D MA$1.62
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—